Suda KJ, Hurley AM, McKibbin T, et al. . Publication of noninferiority clinical trials: changes over a 20‐year interval. Pharmacotherapy 2011;31:833–839.
Gyawali B, Kesselheim AS. US Food and Drug Administration approval of new drugs based on noninferiority trials in oncology: a dangerous precedent? JAMA Oncol 2019;5:607–608.
Rehal S, Morris TP, Fielding K, et al. . Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open 2016;6:e012594.
Riechelmann RP, Alex A, Cruz L, et al. . Non-inferiority cancer clinical trials: scope and purposes underlying their design. Ann Oncol 2013;24:1942–1947.
Tanaka S, Kinjo Y, Kataoka Y, et al. . Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. Clin Cancer Res. 2012;18:1837–1847.
Hwang TJ, Gyawali B. Association between progression-free survival and patients’ quality of life in cancer clinical trials. Int J Cancer 2019;144:1746–1751.
Moher D, Hopewell S, Schulz KF, et al. . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
Aberegg SK, Hersh AM, Samore MH. Empirical consequences of current recommendations for the design and interpretation of noninferiority trials. J Gen Intern Med 2018;33:88–96.
Piaggio G, Elbourne DR, Altman DG, et al. . Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152–1160.
Dunn DT, Copas AJ, Brocklehurst P. Superiority and non-inferiority: two sides of the same coin? Trials 2018;19:499.
Burotto M, Prasad V, Fojo T. Non-inferiority trials: why oncologists must remain wary. Lancet Oncol 2015;16:364–366.
Murthy VL, Desai NR, Vora A, et al. . Increasing proportion of clinical trials using noninferiority end points. Clin Cardiol 2012;35:522–523.
Gøtzsche PC, Hróbjartsson A, Johansen HK, et al. . Ghost authorship in industry-initiated randomised trials. PLoS Med 2007;4:e19.
Head SJ, Kaul S, Bogers AJ, et al. . Non-inferiority study design: lessons to be learned from cardiovascular trials. Eur Heart J 2012;33:1318–1324.
European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. Doc. Ref. EMEA/CHMP/SWP/4447/00 corr 2. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessment-medicinal-products-human-use-first-version_en.pdf. Accessed November 3, 2019.